Studies in liver and breast have indicated that extracellular matrix plays a critical role in limiting the growth and promoting the differentiation of epithelial cells. However, the signaling mechanism that leads to inhibition of over-growth of epithelial cells is not well understood. Recently, we performed a mutational analysis on ITGA7 gene (ITGA7). We found mutations of ITGA7 in prostate cancer, hepatocellular carcinoma, leiomyosarcoma and glioblastoma multiforme with frequencies ranging from 25% to 83%. Many of these mutations caused truncation, micro-deletion or frameshift of the protein. Interestingly, patients with ITGA7 mutations had higher rate of clinical relapse in both prostate cancer and hepatocellular carcinoma. Mouse model of PC3 and Du145 xenografted prostate tumors showed a dramatic reduction in tumor volume, rate of metastasis and rate of mortality when expression of ITGA7 was restored in these cell lines. ITGA7 induced the expression of cyclin dependent kinase inhibitor 3 (CDKN3) and RACGAP1. siRNA knocking down of CDKN3 and RACGAP1 completely reversed the growth inhibition effect of ITGA7, while only partially reversed the migration inhibition activity. Recently, Annexin V staining and TUNEL assays indicated that over-expression of ITGA7 induced apoptosis in PC3 cells. Through a Yeast two-hybrid system, we identified that the C-terminus of ITGA7 interacted with HtrA2, a cell death protein. A 30 amino acid motif located in the C-terminus of ITGA7 was identified as critical for its interaction with HtrA2. Expression of ITGA7 induced protease activity of HtrA2. siRNA knocking down of HtrA2 abolished the cell death induction by ITGA7. Separately, expression of ITGA7 induced the kinase activity of integrin link kinase (ILK). Interestingly, we also found that ILK, a serine/threonine kinase and structural protein associated with integrins and the cytoskeleton, bound and phosphorylated a tumor suppressor gene called myopodin, which regulates cell growth and cell motility. Based on these preliminary data, we hypothesize that ITGA7 activates HtrA2 and ILK signaling pathways to achieve induction of apoptosis, cell growth inhibition and migration deceleration. In this study, we propose: 1) To elucidate the role of ITGA7/HtrA2 interaction in mediating cell death by analyzing the mutant ITGA7 molecule defective of binding with HtrA2 in PC3 and DU145 cells;2) To investigate the role of ILK/myopodin interaction in ITGA7 regulated cell motility and cell growth by analyzing myopodin defective cell system;3) To study the ITGA7 knock-out mouse strains to investigate the biological role of ITGA7 in prostate gland tissue development, cell differentiation and tumorigenesis;and 4) To investigate whether restoration of ITGA7 protein expression is a viable approach for suppressing prostate cancer.
The project is to investigate how integrin a7 dictates cell growth, migration and cell death in prostate gland, what role integrin a7 plays in prostate gland organogenesis, and whether restoration of integrin a7 expression has a role in potential gene therapy for prostate cancer.
